STK11 mutation induces non-inflammatory TME and could be an essential factor in primary immunotherapy resistance in KRAS-mutated NSCLC patients, [25,79] According to Judd et al., 23% of KRAS-mutated NSCLC patients also have STK11 mutations [18]. This evidence concerns the gene STK11 and non-small cell lung carcinoma.